Respiratory Department, 16507Ramón y Cajal Hospital and Alcala de Henares University, IRYCIS, Madrid, Spain.
Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), 137662Université Européenne de Bretagne, Brest, France.
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620967760. doi: 10.1177/1076029620967760.
Among patients with pulmonary embolism (PE), various permutations of normal or abnormal cardiac troponin results and normal or abnormal echocardiographic right ventricular function are encountered in clinical practice. We aimed to explore whether there is a true gradient of risk based on troponin and echocardiographic results. This study included normotensive patients with PE from the PROgnosTic valuE of CT scan in hemodynamically stable patients with acute symptomatic pulmonary embolism (PROTECT) study. Patients were categorized as having -Troponin/-Echo, -Troponin/+Echo, +Troponin/-Echo, and +Troponin/+Echo. The primary outcome was 30-day "complicated course," including death from any cause, hemodynamic collapse, or recurrent PE. Secondary outcomes included individual adverse event rates. Of the 834 patients who had echocardiographic and troponin results, 569 patients (68%) had -Troponin/-Echo, 126 patients (15%) had -Troponin/+Echo, 74 patients (8.9%) had +Troponin/-Echo, and 65 patients (7.8%) had +Troponin/+Echo. The incidence of 30-day complicated course was 4.6% in patients with -Troponin/-Echo, 11.9% in patients with -Troponin/+Echo, 13.5% in patients with +Troponin/-Echo, and 16.9% in patients with +Troponin/+Echo (P for trend <0.001). In the subgroup of patients with a high-risk sPESI (i.e., intermediate-risk according to the ESC guidelines) (n = 527), the incidence of 30-day complicated course was 14.9% in patients with -Troponin/+Echo, 18.5% in patients with +Troponin/-Echo, and 17.5% in patients with +Troponin/+Echo (P for trend <0.01). In patiens with PE, there seems to be a risk gradient based on troponin and echocardiographic results. This study did not detect a significant risk difference in those with +Troponin/-Echo compared with -Troponin/+Echo.
在患有肺栓塞(PE)的患者中,临床上会遇到各种正常或异常的心脏肌钙蛋白结果和正常或异常的超声心动图右心室功能的组合。我们旨在探讨基于肌钙蛋白和超声心动图结果是否存在真正的风险梯度。这项研究包括来自 PROgnosTic valuE of CT scan in hemodynamically stable patients with acute symptomatic pulmonary embolism(PROTECT)研究中的血压正常的 PE 患者。患者分为 -Troponin/-Echo、-Troponin/+Echo、+Troponin/-Echo 和 +Troponin/+Echo。主要结局是 30 天的“复杂病程”,包括任何原因引起的死亡、血流动力学崩溃或复发性 PE。次要结局包括各不良事件的发生率。在有超声心动图和肌钙蛋白结果的 834 名患者中,569 名患者(68%)为 -Troponin/-Echo,126 名患者(15%)为 -Troponin/+Echo,74 名患者(8.9%)为 +Troponin/-Echo,65 名患者(7.8%)为 +Troponin/+Echo。-Troponin/-Echo 患者的 30 天复杂病程发生率为 4.6%,-Troponin/+Echo 患者为 11.9%,+Troponin/-Echo 患者为 13.5%,+Troponin/+Echo 患者为 16.9%(趋势 P<0.001)。在高危 sPESI(即根据 ESC 指南为中危)亚组患者(n=527)中,-Troponin/+Echo 患者的 30 天复杂病程发生率为 14.9%,+Troponin/-Echo 患者为 18.5%,+Troponin/+Echo 患者为 17.5%(趋势 P<0.01)。在患有 PE 的患者中,似乎存在基于肌钙蛋白和超声心动图结果的风险梯度。本研究未检测到+Troponin/-Echo 与 -Troponin/+Echo 之间的显著风险差异。